Objective

In recent years the treatment paradigm for metastatic colorectal cancer (mCRC) has evolved in complexity to include newly developed targeted therapeutics. In 2004 bevacizumab (bvz) [Avastin] became the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised angiogenic trial in advanced metastatic colorectal cancer. Nevertheless, over the past six year period emerging data now indicates that bvz fails to produce an enduring clinical response in a high proportion of patients. Delivery of the drug as part of a combination treatment regimen in mCRC elicits transitory improvements in the form of tumour stasis or shrinkage. Inevitably however, the tumours begin to re-grow and the disease progresses. It is now universally agreed that the future use of bvz in mCRC (and other cancers) is likely to
be greatly influenced by the availability of predictive biomarkers to allow selection of patients who will attain the greatest benefit. The ANGIOPREDICT paradigm relies on a modular platform for the integrated discovery and validation of predictive pharmacogenomic biomarkers for combination bvz therapy in mCRC. Through initiation of a multi-centre clinical trial, early discovery findings will be validated for markers of Intrinsic Resistance to therapy. Parallel optimization of companion in vitro diagnostic tests (IVDs) through exploitation of proven SME development and validation strategies will ensure a cross-sectoral benefit to the cancer patient, prescribing physician and more broadly, across European and global public health networks. Crucially, leading SME partners will expand business portfolios into a well-defined market, progress novel intellectual property and access several in-licensing opportunities. ANGIOPREDICT uniquely unites world-class molecular diagnostic biomarker discovery SMEs with leading clinical and academic entities to identify a new generation of individualized methods for predicting response to combination bvz therapy.

Field of science
/social sciences/economics and business/business and management/commerce
/medical and health sciences/health sciences/public and environmental health
/social sciences/economics and business
/medical and health sciences/clinical medicine/oncology/cancer
/medical and health sciences/clinical medicine/oncology/cancer/colorectal cancer

Programme(s)

Topic(s)

Call for proposal
FP7-HEALTH-2011-two-stage

Funding Scheme
CP-FP - Small or medium-scale focused research project

Coordinator
ROYAL COLLEGE OF SURGEONS IN IRELAND
Participants (10)

VIB VZW

Belgium

EU contribution € 677 500

Address
Rijvisschestraat 120
9052 Zwijnaarde - Gent

Activity type
Research Organisations

Website
Contact the organisation

Administrative Contact
Rik Audenaert (Mr.)

EPIGENOMICS AG

Germany

EU contribution € 794 625

Address
Kleine Praesidentenstr 1
10178 Berlin

Activity type
Private for-profit entities
(excluding Higher or Secondary Education Establishments)

Website
Contact the organisation

Administrative Contact
Annett Freitag (Ms.)

SOMANTIX BV

Netherlands

EU contribution € 587 800
<table>
<thead>
<tr>
<th><strong>Address</strong></th>
<th><strong>Activity type</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Bronkhorstlann 10-92 3723 MB Bilthoven</td>
<td>Private for-profit entities (excluding Higher or Secondary Education Establishments)</td>
</tr>
<tr>
<td><a href="#">Website</a></td>
<td><a href="#">Contact the organisation</a></td>
</tr>
<tr>
<td><strong>Administrative Contact</strong></td>
<td><strong>Laurens Van Der Flier (Dr.)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Address</strong></th>
<th><strong>Activity type</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>172 Rathgar Road Rathgar Dublin 6 Dublin</td>
<td>Private for-profit entities (excluding Higher or Secondary Education Establishments)</td>
</tr>
<tr>
<td><a href="#">Website</a></td>
<td><a href="#">Contact the organisation</a></td>
</tr>
<tr>
<td><strong>Administrative Contact</strong></td>
<td><strong>Mairin Rafferty (Dr.)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Address</strong></th>
<th><strong>Activity type</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>De Boelelaan 1105 1081 HV Amsterdam</td>
<td>Higher or Secondary Education Establishments</td>
</tr>
<tr>
<td><a href="#">Website</a></td>
<td><a href="#">Contact the organisation</a></td>
</tr>
<tr>
<td><strong>Administrative Contact</strong></td>
<td><strong>B Ylstra (Dr.)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Address</strong></th>
<th><strong>Activity type</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Seminarstrasse 2 69117 Heidelberg</td>
<td>Higher or Secondary Education Establishments</td>
</tr>
<tr>
<td><a href="#">Website</a></td>
<td><a href="#">Contact the organisation</a></td>
</tr>
<tr>
<td><strong>Administrative Contact</strong></td>
<td><strong><a href="#">RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG</a></strong></td>
</tr>
</tbody>
</table>
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland
EU contribution
€ 634 800

Address
Belfield
4 Dublin

Activity type
Higher or Secondary Education Establishments

Website
Contact the organisation

Administrative Contact
Matthias Ebert (Prof.)

CANCER TRIALS IRELAND CLG

Ireland
EU contribution
€ 277 200

Address
Innovation House Dcu Alpha
Finglas Road Old
D11 KXN4 Dublin 11

Activity type
Other

Website
Contact the organisation

Administrative Contact
Donal Doolan (Mr.)

PINTAIL LTD

Ireland
EU contribution
€ 152 000

Address
Springhill Avenue 77
A94 K542 Blackrock

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Website
Contact the organisation

Administrative Contact
Verena Murphy (Dr.)
STICHTING VU
Netherlands
EU contribution
€ 436 200

Address
De Boelelaan 1105
1081 HV Amsterdam

Activity type
Higher or Secondary Education Establishments

Website
Contact the organisation

Administrative Contact
Bauke Ylstra (Dr.)

Last update: 5 June 2017
Record number: 102319

Permalink: https://cordis.europa.eu/project/id/278981

© European Union, 2020